Industry: Healthcare
Published Date: February-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 237
Report ID: PMRREP25954
The global market for gastric electrical stimulators is forecast to expand at a CAGR of 6.4% and thereby increase from a value of US$250.0 Mn in 2023, to US$386.0 Mn by the end of 2030.
|
Attributes |
Key Insights |
|
Market Size (2023E) |
US$250.0 Mn |
|
Projected Market Value (2030F) |
US$386.0 Mn |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
6.4% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
5.9% |
Gastric electrical stimulation (GES), also known as gastric pacing or implantable gastric stimulation (IGS), involves the utilization of specialized devices to administer electrical stimulation to the stomach for the treatment of gastroparesis. Additionally, it is employed as an intervention for overweight and obese individuals. GES serves as an alternative therapy for medically refractory gastroparesis. The gastric electrical stimulator is a compact, battery-operated neurostimulator implanted beneath the skin in the lower abdominal region.
Comprising two insulated leads, these wires are implanted in the stomach wall muscle and connected to the neurostimulator. The leads deliver controlled electrical pulses to the antrum portion of the stomach muscle wall. The market for gastric electrical stimulation systems is anticipated to experience growth in the coming years due to factors such as the increasing incidence of gastroparesis, favorable reimbursement policies for gastric electric stimulation, and the rise in obesity rates, coupled with a surge in overweight population.
The worldwide incidence of gastroparesis is on the rise, as highlighted in an October 2022 article published in the United European Gastroenterology Journal (UEG Journal). Notably, gastroparesis-like symptoms (GPLS) are prevalent globally, particularly among diabetic patients. The global prevalence of GPLS is reported at 0.9% overall and 1.3% in individuals with diabetes.
Gastric electrical stimulation is emerging as a promising treatment for weight loss. According to data from the World Health Organization (WHO), global obesity rates have nearly tripled from 1975 to 2016. In 2016, more than 1.9 billion adults aged 18 and older were overweight, with over 650 million classified as obese. Additionally, 39% of adults aged 18 and over were overweight, and 13% were obese. Notably, type 2 diabetes mellitus is most prevalent among individuals with gastroparesis.
Complications Associated with Infection, Bleeding, and Device Issues
The global market for gastric electrical stimulation (GES) faces potential constraints due to complications associated with the technology. These complications include issues such as infection, bleeding, bruising, implant site pain, gastric perforation, lead penetration, bowel obstruction or perforation, irritation or inflammation over the implant site, lead entanglement or erosion, and mechanical or electrical problems with the device.
It is noteworthy that, as of now, no GES devices have received approval from the FDA for the treatment of obesity. In Europe, the Transcend® device (originally developed by Transneuronix and later acquired by Medtronic in 2005) is available for the treatment of obesity.
Availability of Alternative Treatment Therapies
The growth of the gastric electric stimulators market is anticipated to face obstacles due to the availability of alternative treatment therapies and limited support from regulatory bodies. Concerns regarding the risks associated with implant procedures are expected to pose challenges to the market for gastric electric stimulators.
Development in Potential Treatment Options
Ongoing advancements in potential treatment options and the evolution of techniques and devices have significantly broadened the landscape for gastroparesis treatment. The continuous innovation in gastrointestinal disorders, enhanced treatment modalities, and the evolution of surgical instruments and robotic technology have propelled gastrointestinal surgery towards less invasive approaches in recent years. This trend is anticipated to unlock growth opportunities for the market of gastric electric stimulators.
The growing demand for early diagnosis and preventive medical interventions is fueling innovation in the medical industry, especially in the realm of the Internet of Things (IoT). This technology is actively employed to alleviate symptoms associated with gastroparesis and facilitate medication management. Businesses are advised to consider investments in innovative companies and vendors engaged in the development and application of wireless gastric electrical stimulation (GES) devices.
Which is the Leading Market Segment by Type?
High-frequency Gastric Electric Stimulators Lead the Way with an Extended Battery Life, Less Invasive Nature, and Improved Patient-friendliness
The prevailing trend of favoring high-frequency gastric electric stimulators is projected to persist throughout the forecast period. This is attributed to the advantages they offer over low-frequency stimulators, particularly their extended battery life. The increasing popularity of high-frequency stimulators is driven by their less invasive nature and improved patient-friendliness during insertion. Additionally, the growing availability of high-frequency gastric electrical stimulators, coupled with a heightened emphasis on gastroparesis treatment, is poised to propel this segment in the foreseeable future, presenting strategic opportunities for businesses in the market.
What is the Primary Application Area?
Gastroparesis Spearheads on Account of a Unique Treatment Approach
Gastroparesis, a rare condition with limited effectiveness of traditional medication treatments, finds its primary management through gastric electrical stimulation, making it the exclusive therapeutic option. The anticipated growth of the gastric electrical stimulators market is attributed to this unique treatment approach. Additionally, the increasing prevalence of both type 1 and type 2 diabetes, recognized as the primary causes of gastroparesis, is another factor driving the expansion of the gastric electrical stimulators market over the forecast period.
Which is the Largest End User Category?
Demand for Gastroparesis Treatment Procedures Keeps Hospitals at the Forefront of Adoption
The hospitals and clinics segment played a substantial role, primarily due to the growing number of healthcare facilities and an uptick in gastroparesis treatments conducted within these settings. The American Hospital Association (AHA) reported an increase in the number of hospitals in the US, rising from 5,564 in 2017 to 6,093 in 2022. This expansion in hospital infrastructure in the region has contributed to a notable increase in the performance of minimally invasive surgical (MIS) procedures.
Led by the US, North America Leads in Line with More Gastrointestinal Surgical Procedures
The US market is expected to experience growth driven by an increase in gastrointestinal surgical procedures, a high prevalence of gastroparesis, and favorable regulatory and reimbursement policies for Gastric Electrical Stimulation (GES). According to research published in a Wolters Kluwer journal, the prevalence rates of Gastroparesis in the US are reported at 16.8% for type 1 diabetes, 14.0% for type 2 diabetes, and 13.2% for idiopathic cases.
Asia Pacific Represents a Highly Profitable Market as Witnesses a Remarkably Swelling Burden of Chronic Disease Prevalence
The growth in the region can be attributed to the expanding elderly population, the development of healthcare infrastructure, increased awareness about gastric electrical stimulation systems, and a higher incidence of chronic diseases such as obesity, diabetes, and gastrointestinal disorders in developing countries. According to an annual health report by Apollo Hospitals, there has been a 50% increase in the prevalence of early risk factors like obesity and an 18% rise in dyslipidemia (cholesterol irregularities) between 2019 and 2022.
The market is anticipated to undergo substantial expansion and change. Presently, available gastric electric stimulators are utilized in treating refractory gastroparesis and obesity. However, these stimulators, powered by non-rechargeable batteries, are larger and necessitate surgical implantation with subsequent replacement procedures. To address this, companies have devised a prototype of a compact gastric electric stimulator that can be wirelessly recharged and is suitable for endoscopic implantation.
The introduction of smaller, rechargeable, wireless gastric electric stimulation systems creates noteworthy opportunities for both existing players and new entrants in the gastric electrical stimulation systems market. Post the peak of the COVID-19 pandemic, businesses in this sector are making data-driven decisions when considering investments in new device technologies. There is a significant focus on research and development, particularly in advancing the technological capabilities of gastric electric stimulators for the treatment of gastroparesis and obesity.
Supply-side Dynamics
Several factors, including the Rising Gastroparesis Prevalence and, rise in the rate of minimally invasive surgeries, all contribute to the dynamic and rapid expansion of the global Gastric Electrical Stimulators market. Medtronic Plc., IntraPace Inc., ReShape Lifesciences Inc., Changzhou Ruishen Medical Equipment Co. Ltd., Chentao Medical Equipment, Rishena Co. Ltd., and Enterra are market leaders in the manufacturing sector.
The countries of Germany, Japan, China, France, and the US are significant producers of various goods. Japan, leveraging its technological expertise, is poised to revolutionize treatment approaches for conditions such as gastroparesis. The country takes a leading role in shaping the advancement of gastric electrical stimulators, driven by its commitment to promoting healthcare solutions and a meticulous approach to research methodologies.
Several corporations are allocating resources towards expanding their capacity to satisfy the increasing need for stomach electrical stimulators. It is anticipated that these expansions will substantially alter the dynamics of the market, resulting in heightened competition, reduced prices, and an influx of innovative products.
Prominent organizations, including Medtronic Plc., and IntraPace Inc., are at the vanguard of this sector, providing inventive solutions by capitalizing on their technological prowess and vast experience in the electrical stimulators industry. Organizations operating within this sector are focusing on manufacturing technologically advanced products to enhance effectiveness and patient compliance.
Additionally, they establish collaborations with key industry stakeholders, research institutions, and healthcare providers to foster innovation and enhance the development of advanced medical solutions. To distinguish themselves in this highly competitive market, these businesses strive to differentiate their products. They achieve this by providing advanced technologies, and superior quality in their offerings.
New Product Launch
In 2021, IntraPace unveiled the INSPIRES Control wireless stomach electrical stimulator, marking a notable leap in patient-centered technology. This wireless innovation presents a more convenient and patient-friendly option as it eliminates the need for invasive surgery during both installation and removal, potentially transforming the landscape of stomach electrical stimulation therapy.
Market Impact: Compared to conventional gastric electrical stimulators, this novel technology offers a more feasible and minimally invasive option for both installation and removal, marking a significant advancement in patient-centered treatment. Because wireless technology is more convenient and patient-friendly, it is expected to draw in a larger number of patients. This could lead to market expansion and a rise in the use of stomach electrical stimulation therapy.
In March 2020, Medtronic plc introduced the Enterra II 37800 gastric neurostimulator, a programmable implantable device designed to generate mild electrical pulses. This device is specifically developed for treating chronic, intractable nausea and vomiting associated with gastroparesis that is resistant to conventional medications
Market Impact: The treatment of chronic, uncontrollable nausea and vomiting associated with gastroparesis is addressed by this novel implantable device that can be programmed. It is especially effective in cases where normal drugs are not working. Given that this cutting-edge neurostimulator offers a viable and efficient treatment for a previously incurable medical disease, the market is anticipated to develop, possibly leading to higher adoption rates and a larger total market for gastric electrical stimulators.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Type:
By Application:
By End-User:
By Region:
To know more about delivery timeline for this report Contact Sales
The market is anticipated to grow at a CAGR of 6.4% during the projected period.
The gastric electrical stimulators market was valued at US$250 million in 2023.
The US held the largest market share in 2023.
Some of the prominent players in the market are Medtronic Plc., IntraPace Inc., ReShape Lifesciences Inc., Changzhou Ruishen Medical Equipment Co. Ltd., Chentao Medical Equipment, Rishena Co. Ltd., and Enterra.
The gastroparesis segment is expected to grow at the fastest CAGR during the forecast period.
